Filing Flows

Filing Flows › Companies › Cocrystal Pharma › Cash flow

Cocrystal Pharma cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.5M in Q2 2026 · −$8.0M over twelve months

Operating cash flow−$2.5M
Free cash flow−$2.5M

Analysis

In Q2 2026, Cocrystal Pharma generated −$2.5M of operating cash flow. That is $361K less than in Q2 2025 (−$2.2M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$8.0M; the largest uses were operating cash flow ($8.0M); the cash balance fell by $2.6M.

Operating cash flow was −$2.5M against net income of −$3.2M. The largest differences: payables +$378K, prepaid and other assets +$160K, stock-based pay +$92K.

Free cash flow

Cocrystal Pharma: free cash flow by quarterCocrystal Pharma: free cash flow by quarter−$5.1MQ3 2024−$3.2MQ4 2024−$2.9MQ1 2025−$2.2MQ2 2025−$1.4MQ3 2025−$1.7MQ4 2025−$2.3MQ1 2026−$2.5MQ2 2026
Operating cash flow less capital spending.
Cocrystal Pharma: operating cash flow against capital spendingCocrystal Pharma: operating cash flow against capital spendingOperating cash flowCapital spending−$5.1M$0Q3 2024−$3.2M$0Q4 2024−$2.9M$0Q1 2025−$2.2M$0Q2 2025−$1.4M$0Q3 2025−$1.7M$0Q4 2025−$2.3M$0Q1 2026−$2.5M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$2.5M, Capital spending $0.

Capital allocation, year by year

Cocrystal Pharma: where the cash came from (up) and went (down), by fiscal yearCocrystal Pharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$12.7MFY2021: Net borrowing −$39KFY2021: Shares issued $38.5MFY2021: Capital spending −$52K$38.5MFY2021FY2022: Operating cash flow −$21.4MFY2022: Net borrowing −$27KFY2022: Capital spending −$74KFY2022FY2023: Operating cash flow −$14.7MFY2023: Net borrowing −$7KFY2023: Shares issued $4.0MFY2023: Capital spending −$118K$4.0MFY2023FY2024: Operating cash flow −$16.5MFY2024: Capital spending −$8KFY2024FY2025: Operating cash flow −$8.2MFY2025: Shares issued $154KFY2025: Capital spending −$12K$154KFY2025
Over these 5 years operating cash flow totalled −$73.5M; the largest uses were operating cash flow ($73.5M) and capital spending ($264K). Cash-flow statements as filed.

Where the cash came from and went

Cocrystal Pharma: sources (+) and uses (−) of cash, Q2 2026Cocrystal Pharma: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$2.5MCash drawn (+) / kept (−)$2.5M
Cocrystal Pharma: sources (+) and uses (−) of cash, TTM to Q2 2026Cocrystal Pharma: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$8.0MNot reconciled$5.4MCash drawn (+) / kept (−)$2.6M

From profit to cash

Cocrystal Pharma: net income to operating cash flow, Q2 2026Cocrystal Pharma: net income to operating cash flow, Q2 2026Net income−$3.2MDepreciation & amortization$12KStock-based pay$92KPayables$378KPrepaid and other assets$160KOperating cash flow−$2.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q2 2026−$2.5M$2.5M−$2.5M
Q1 2026−$2.3M$2.3M−$2.3M
Q4 2025−$1.7M$704K−$1.7M
Q3 2025−$1.4M−$3.0M−$1.4M
Q2 2025−$2.2M$2.2M−$2.2M
Q1 2025−$2.9M$2.9M−$2.9M
Q4 2024−$3.2M$3.2M−$3.2M
Q3 2024−$5.1M$5.1M−$5.1M

Cocrystal Pharma: income statement and cash flow

Cocrystal Pharma, Q2 2026: revenue $105K. The chart follows the revenue to costs, profit and cash.

Cocrystal Pharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.